CN114437193A - Gold-melittin nano hybrid and application thereof - Google Patents
Gold-melittin nano hybrid and application thereof Download PDFInfo
- Publication number
- CN114437193A CN114437193A CN202210112859.6A CN202210112859A CN114437193A CN 114437193 A CN114437193 A CN 114437193A CN 202210112859 A CN202210112859 A CN 202210112859A CN 114437193 A CN114437193 A CN 114437193A
- Authority
- CN
- China
- Prior art keywords
- melittin
- gold
- nano
- nanohybrid
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a gold-melittin nano hybrid and application thereof, relating to a preparation method of the nano hybrid, comprising the following steps: dissolving melittin in a solution containing NH2Adding HEPES and HAuCl into a mixed solution of-PEG-SH, ethanol and water in sequence under heating and stirring4·XH2Reacting until the solution turns white from yellow to obtain an Au-peptide precursor; mixing HEPES and HAuCl4·XH2Mixing O and water, heating and stirring until the solution turns into purple red to obtain a nano gold solution; and mixing the Au-peptide precursor and the nano-gold solution, heating and stirring, slowly dropwise adding polyacrylamide hydrochloride, and reacting for 5-10 min to obtain the gold-melittin nano hybrid. The gold-melittin nano hybrid prepared by the invention has the characteristics of good stability, high safety, good biocompatibility and the like, and has excellent effects on promoting wound healing, inhibiting inflammation, eliminating/reducing skin wrinkles and the like.
Description
Technical Field
The invention belongs to the technical field of bioengineering, relates to medical application of melittin, and particularly relates to a gold-melittin nano hybrid and application thereof.
Background
Melittin (melittin) is a 26-residue basic polypeptide belonging to cationic lytic peptides, accounting for about 50% of dry weight of bee venom, and is a major component with pharmacological and biological activities in bee venom. Melittin is widely used in anti-inflammatory, anti-tumor, blood pressure lowering, analgesic, antibacterial, etc. and has anti-inflammatory effect 100 times stronger than that of hydrocortisone with the same dosage. In addition, melittin, also known as a natural substitute for botulinum toxin, is a very good skin care raw material, and can stimulate skin to produce collagen, tighten and pull, smooth fine wrinkles and restore elasticity. Melittin as a monomer exists in a neutral aqueous solution in a random coil structure, and along with the change of pH and ionic strength, melittin can be self-crosslinked to form a spiral tetramer structure, the surface of the spiral structure is the first 21 polar amino acids, and the other surface is non-polar amino acids, so that the melittin is easy to be fused into and damage a phospholipid bilayer and generates cytotoxicity; in addition, melittin was found to be unstable in saline, PBS, and to degrade faster, which is consistent with the inherent drawbacks of polypeptides. To solve/improve this inherent drawback, nanotechnology provides a bottom-up approach.
The nano gold (AuNp) is gold micro particles, the diameter of the nano gold (AuNp) is 1-100 nm, the nano gold has high electron density, dielectric property and catalytic action, can be combined with various biological macromolecules, and does not influence the biological activity of the nano gold. The gold nanoparticles with different particle sizes can be conveniently prepared by adopting a chloroauric acid reduction method, and the color of the gold nanoparticles is red to purple according to the diameter. At present, the technology of nano gold particle coupling peptide therapy is rapidly developed, and more nano gold is applied to clinical tests due to the inherent advantages of inertia, low toxicity, economic cost and the like.
Melittin is unstable in the physiological environment in vivo, is easily degraded, affects the effect of polypeptide, and has certain toxicity. The direct combination of the nanogold and the melittin can not avoid the harsh reaction condition of converting gold ion precursors into gold atomic nuclei, thereby being difficult to ensure that the melittin still has the biological activity of the melittin after being combined with the nanogold. This has led to the fact that melittin has not been used to date as well as being effective. Therefore, it is very important to develop a biological material which can enhance the stability of melittin in vivo physiological environment, still has the biological activity of melittin and has low toxicity.
Disclosure of Invention
The invention aims to solve the problems that melittin is unstable in the physiological environment in vivo, is easy to degrade, influences the polypeptide effect and has certain toxicity.
In view of the above, the present invention provides a gold-melittin nanohybrid to address this need in the art.
In one aspect, the present invention relates to a method for preparing a gold-melittin nano hybrid, which comprises: dissolving melittin in a solution containing NH2Adding HEPES and HAuCl into a mixed solution of-PEG-SH, ethanol and water in sequence under heating and stirring4·XH2Reacting until the solution turns white from yellow to obtain an Au-peptide precursor; mixing HEPES and HAuCl4·XH2Mixing O and water, heating and stirring until the solution turns into purple red to obtain a nano gold solution; and mixing the Au-peptide precursor and the nano-gold solution, heating and stirring, slowly dropwise adding polyacrylamide hydrochloride, and reacting for 5-10 min to obtain the gold-melittin nano hybrid.
Further, in the preparation method of the gold-melittin nano hybrid provided by the invention, the melittin amino acid sequence is shown as SEQ ID No. 1; the SEQ ID No.1 is: Ac-GIGAVLKVLTTGLPALISWIKRKRQQ-NH2。
Furthermore, in the preparation method of the gold-melittin nano hybrid provided by the invention, 2mg of melittin and 0.01mmol of HAuCl are mixed4·XH2And O, preparing the gold-melittin nano hybrid.
Further, in the preparation method of the gold-melittin nano hybrid provided by the invention, the heating and stirring conditions are 50 ℃, and the rotation speed is 500rpm for stirring.
In particular, the invention provides goldIn the preparation method of melittin nano hybrid, every 2mg of melittin is matched with 0.5mL of NH with the concentration of 4mg/mL2Mixing and dissolving PEG-SH aqueous solution, 0.5mL of absolute ethyl alcohol and 1.25mL of pure water; in the preparation of Au-peptide precursor, 4-hydroxyethylpiperazine ethanesulfonic acid (HEPES) (100mM, pH7.4, dissolved in pure water) was added in an amount of 2.25mL, and HAuCl was added4·XH2The amount of O (10mM, dissolved in pure water) added was 0.5 mL; in the preparation of the nanogold solution, 2.25mL of pure water and 0.5mL of HAuCl were added to 2.25mL of HEPES (100mM in pure water)4·XH2O (10 mM); after the Au-peptide precursor is mixed with the nano gold solution, the dripping concentration of the polyacrylamide hydrochloride PAH is 4 mg/mL.
The invention applies nanotechnology to combine melittin and nanogold, and the prepared gold-melittin nano hybrid shows excellent effect in the aspect of eliminating/reducing skin wrinkles. The medicine containing gold-melittin nano hybrid as an active ingredient is used for paralysis relaxation of facial expression muscles, and achieves the effects of improving facial contour and eliminating or reducing wrinkles; can be used for treating wound skin epidermis, and is effective in promoting wound healing and inhibiting inflammation. The invention further claims the application of the gold-melittin nano hybrid in skin external preparations for eliminating/reducing skin wrinkles, skin external preparations for changing facial contours, medicines for promoting skin wound healing and anti-inflammatory medicines. Based on the above applications, the present invention further claims the gold-melittin nano-hybrid as a pharmaceutical composition, a drug for promoting skin wound healing, an anti-inflammatory drug, a drug for paralysis and relaxation of mammalian muscles.
Compared with the prior art, the invention has the following beneficial effects or advantages:
(1) the invention provides a gold-melittin nano hybrid, which has excellent safety within the concentration range of less than 0.0025 mg/mL;
(2) the invention provides a gold-melittin nano hybrid, and a medicine prepared from the gold-melittin nano hybrid can obviously improve the healing rate of skin wounds;
(3) the invention provides a gold-melittin nano hybrid, and a medicament prepared from the same has excellent anti-inflammatory effect;
(4) the invention provides a gold-melittin nano hybrid, and a skin external preparation prepared from the gold-melittin nano hybrid is used for relaxing facial expression muscle paralysis, and achieves the effects of improving facial contour and eliminating or reducing wrinkles.
Drawings
FIG. 1 is a melittin HPLC chart
FIG. 2 is an ESI-MS diagram of melittin
FIG. 3 is a graph showing the effect of gold-melittin nano-hybrid on the viability of RAW264.7 cells.
FIG. 4 is a diagram showing the morphological observation of RAW264.7 cells by using gold-melittin nano-hybrid at different concentrations.
Fig. 5 is a photograph of a wound size measurement of an anti-inflammatory model of skin wounds.
FIG. 6 is a statistical plot of wound healing for an anti-inflammatory model of skin wounds; expressed as p < 0.05.
FIG. 7 is a graph of HE staining of an anti-inflammatory model of skin wounds.
FIG. 8 is a graph showing the result of VIISA image acquisition before and after the gold-melittin nano hybrid is applied to the eyes.
Detailed Description
The following examples are given to illustrate the technical aspects of the present invention, but the present invention is not limited to the following examples.
Example 1
This example provides a test for the preparation of gold-melittin nanohybrids.
(1) Preparation of Au-peptide precursor
Dissolving 2mg melittin in 0.5ml NH2In a mixed solution of-PEG-SH (4mg/mL, dissolved in pure water), 0.5mL of absolute ethyl alcohol and 1.25mL of pure water, carrying out ultrasonic oscillation for 5-10 min to completely dissolve the polypeptide; then, the mixture was poured into a clean 50mL beaker, and stirred with a magnetic stirrer at 50 ℃ and 500rpm, and 2.25mL of HEPES (100mM, pH7.4, dissolved in pure water) and 0.5mL of HAuCl were added in this order4·XH2O (10mM, dissolved in pure water) reacts for 30-60 s, and the solution turns white from yellow, namely, an Au-peptide precursor is formed.
Wherein, the melittin amino acid sequence is as follows:
Ac-GIGAVLKVLTTGLPALISWIKRKRQQ-NH2。
(2) preparation of nano gold solution
2.25mL of HEPES (100mM, pH7.4, dissolved in pure water), 2.25mL of pure water, 0.5mL of HAuCl4·XH2O (10mM) is added into a clean 50mL beaker in sequence, a magnetic stirrer is used for stirring reaction for 30s at the temperature of 50 ℃ and the rotating speed of 500rpm, and when the solution turns to purple red, the nano gold solution is formed.
(3) Preparation of gold-melittin nano hybrid
And (3) after the synthesized Au-peptide precursor is formed in the nano-gold solution in the step (2), immediately pouring the Au-peptide precursor into the nano-gold solution, stirring and reacting for 1min at the rotation speed of 300rpm in a magnetic stirrer at 50 ℃, then absorbing 0.2mL of polyacrylamide hydrochloride (PAH) (4mg/mL, dissolved in pure water), slowly dropwise adding into the solution, and reacting for 5-10 min to complete the preparation of the gold-melittin nano hybrid. Purification to homogeneity was carried out by preparative C18 reverse phase HPLC method. Molecular weight was determined by electrospray ionization mass spectrometry (ESI-MS). And (4) freeze-drying on a freeze dryer to obtain the target product.
FIG. 1 is HPLC chart of melittin, which can be obtained from FIG. 1, and the melittin shows single chromatographic peak at 11.18min, and its purity is above 97% by HPLC. FIG. 2 is an ESI-MS graph of melittin, which is obtained from FIG. 2 and has a molecular weight of 2888.54 Da.
Example 2
This example provides a test for safety evaluation of gold-melittin nano-hybrids.
Inoculating RAW264.7 cells into a 96-well plate, putting the 96-well plate into an incubator overnight, after the cells are completely attached to the wall, sequentially adding prepared 8 gold-melittin nano hybrid solutions with different concentrations into the 96-well plate, wherein each well is 100 mu L, after the gold-melittin nano hybrid and the RAW264.7 cells act for 24h, detecting the influence of the gold-melittin nano hybrid solution with each concentration on the activity of the RAW264.7 cells by adopting a CCK8 method, and the detection result of the CCK8 method is shown in figure 3.
4 gold-melittin nano-hybrid with different concentrations and without obvious toxic and side effects on RAW264.7 cells act on the RAW264.7 cells for 24 hours, the influence of the gold-melittin nano-hybrid on the morphology of the cells is observed by an electron microscope, and the observation result is shown in figure 4.
As can be seen from FIGS. 3 and 4, CCK8 and morphological results indicate that the gold-melittin nano-hybrid has no obvious toxic and side effects on RAW264.7 cells in the concentration range of less than 0.0025 mg/mL.
Example 3
This example provides a test of the anti-inflammatory effect of a gold-melittin nano-hybrid for treating skin wounds.
(1) Animal experiment of gold-melittin nano hybrid for treating skin wound and anti-inflammatory effect
12C 57 male mice with the age of 8-10 weeks are randomly divided into 4 groups, 3 mice in each group are subjected to back damage, LPS is injected into subcutaneous damage positions in other 3 groups except a blank group, and a skin wound model is successfully constructed after 3 days. ddH was applied to 3 groups of LPS-injected subcutaneous lesions2O (model group), melittin (melittin group) 0.1mg/mL, and gold-melittin nano-hybrid (gold-melittin nano-hybrid group) 0.1 mg/mL. Each group was applied to the wound site at a dose of 100. mu.L each time, once every 3 days, and 14 days later, the experiment was terminated, and the size of the wound site was measured and photographed, and the healing condition after injury was calculated, and the anti-inflammatory effect was evaluated.
The wound sizes were photographed at 0, 3, 6, and 14 days, respectively, and the results of photographing the wound sizes are shown in fig. 5, and the statistical results of wound healing are shown in fig. 6. Statistical results show that when a wound model is constructed on the surface of the skin of a mouse for 6 days, compared with a model group, the healing rate of the skin is remarkably improved (p is less than 0.05) after the treatment by using the gold-melittin nano hybrid, and the gold-melittin nano hybrid has an obvious anti-inflammatory effect on an inflammation model induced by LPS.
(2) The pathological test of the gold-melittin nano hybrid for treating skin wounds and resisting inflammation comprises the steps of dividing 3C 57 mice of 6-8 weeks old, female and male into 3 groups, injecting LPS (lipopolysaccharide) at subcutaneous injury positions after the backs of the 3 groups of mice are damaged, smearing ddH (dichloro diphenyl trichloroethane) after 3 days of success of a skin wound model, and carrying out anti-inflammatory treatment on the skin wounds2O (model group), 0.1mg/mL melittin (melittin group) and 0.1mg/mL gold-melittin nano-hybrid (gold-melittin nano-hybrid group) for treatmentTreatment, each group was applied with 200 μ L each time, and 3 days after application, the HE sections of the back skin were evaluated for anti-inflammatory effects. HE slice results are shown in fig. 7.
As can be seen from the HE slice results of fig. 7, inflammatory cells of female/male mice treated with gold-melittin nano-hybrid were significantly reduced compared to the control group and melittin group.
Example 4
This example provides a test for anti-wrinkle efficacy of gold-melittin nano-hybrid.
Randomly selecting 3 healthy subjects, applying gold-melittin nano hybrid with the concentration of 0.1mg/mL on eyes, collecting images of the subjects by adopting VIISA, and comparing the change conditions of wrinkles and textures of the eyes before and after the gold-melittin nano hybrid is applied. The statistical results of wrinkle indexes before and after smearing the gold-melittin nano hybrid are shown in table 1. The result of image acquisition by VIISA is shown in fig. 8.
TABLE 1 statistical table of wrinkle index before and after smearing gold-melittin nano hybrid
As can be seen from the results of table 1 and fig. 8, the gold-melittin nano hybrid is applied to the eyes to relax paralysis of the facial expression muscles, so as to achieve the effects of improving facial contour and eliminating or reducing wrinkles. The eye wrinkle changes before and after the gold-melittin nano hybrid is coated are compared to find that the eye wrinkle textures of the testee with more eye wrinkles are obviously improved after the gold-melittin nano hybrid is coated on the testee. For verifier 3 with a wrinkle index of 36% before use, the wrinkle index after use reached 80%, and the improvement reached up to 122%.
As described above, the present invention can be preferably implemented, and the above-mentioned embodiments only describe the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various changes and modifications of the technical solution of the present invention made by those skilled in the art without departing from the design spirit of the present invention shall fall within the protection scope defined by the present invention.
Claims (13)
1. A preparation method of gold-melittin nano hybrid is characterized by comprising the following steps:
dissolving melittin in a solution containing NH2Adding HEPES and HAuCl into a mixed solution of-PEG-SH, ethanol and water in sequence under heating and stirring4·XH2Reacting until the solution turns white from yellow to obtain an Au-peptide precursor;
HEPES, HAuCl4·XH2O and water are mixed, heated and stirred until the solution turns to purple red to obtain a nano gold solution;
mixing, heating and stirring the Au-peptide precursor and the nano-gold solution, slowly dropwise adding polyacrylamide hydrochloride to react for 5-10 min to obtain the gold-melittin nano hybrid;
the amino acid sequence of the melittin is shown as SEQ ID No.1, and the SEQ ID No.1 is: Ac-GIGAVLKVLTTGLPALISWIKRKRQQ-NH2。
2. The method of claim 1, wherein the melittin is administered in an amount of 0.01mmol HAuCl per 2mg of melittin4·XH2And O, preparing the gold-melittin nano hybrid.
3. The method of claim 1, wherein the heating and stirring conditions are 50 ℃ and 500 rpm.
4. A gold-melittin nanohybrid, characterized in that it is prepared by the method according to any one of claims 1 to 3.
5. The use of the gold-melittin nanohybrid of claim 4 in a skin external preparation for eliminating/reducing skin wrinkles.
6. The use of the gold-melittin nanohybrid of claim 4 in a skin external preparation for altering facial contours.
7. The use of the gold-melittin nanohybrid of claim 4 in a medicament for promoting healing of skin wounds.
8. The use of the gold-melittin nanohybrid of claim 4 in anti-inflammatory drugs.
9. A skin external preparation comprising the gold-melittin nanohybrid of claim 4.
10. A pharmaceutical composition comprising the gold-melittin nanohybrid of claim 4.
11. A medicament for promoting healing of skin wounds, comprising the gold-melittin nanohybrid of claim 4.
12. An anti-inflammatory agent comprising the gold-melittin nanohybrid of claim 4.
13. A medicament for paralysis of muscle relaxation in a mammal, comprising the gold-melittin nanohybrid of claim 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210112859.6A CN114437193A (en) | 2022-01-29 | 2022-01-29 | Gold-melittin nano hybrid and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210112859.6A CN114437193A (en) | 2022-01-29 | 2022-01-29 | Gold-melittin nano hybrid and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114437193A true CN114437193A (en) | 2022-05-06 |
Family
ID=81371495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210112859.6A Pending CN114437193A (en) | 2022-01-29 | 2022-01-29 | Gold-melittin nano hybrid and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114437193A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015190849A1 (en) * | 2014-06-13 | 2015-12-17 | 주식회사 휴메딕스 | Melittin-polyethylene glycol conjugate and pharmaceutical composition containing same |
| KR20170015852A (en) * | 2015-07-31 | 2017-02-09 | 이화여자대학교 산학협력단 | Novel cell penetrating peptide |
| CN108210883A (en) * | 2018-01-19 | 2018-06-29 | 东南大学 | A kind of nanometer reagent based on melittin and its preparation method and application |
| CN109692327A (en) * | 2017-10-23 | 2019-04-30 | 华中科技大学 | A kind of application of the nano particle of the application and delivery melittin of melittin |
| CN111909241A (en) * | 2020-07-09 | 2020-11-10 | 西安交通大学医学院第一附属医院 | Polypeptide nano hybrid and preparation method and application thereof |
| US20210244823A1 (en) * | 2018-05-04 | 2021-08-12 | Twinpigbiolab Inc. | Targeting m2-like tumor-associated macrophages by using melittin-based proapoptotic peptide |
| CN113512092A (en) * | 2021-06-28 | 2021-10-19 | 陕西未来多肽生物科技有限公司 | Polypeptide nano hybrid and application thereof |
| CN113952315A (en) * | 2021-11-08 | 2022-01-21 | 苏州迪拉纳生物科技有限公司 | Anticancer medicine and its prepn and application |
-
2022
- 2022-01-29 CN CN202210112859.6A patent/CN114437193A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015190849A1 (en) * | 2014-06-13 | 2015-12-17 | 주식회사 휴메딕스 | Melittin-polyethylene glycol conjugate and pharmaceutical composition containing same |
| KR20170015852A (en) * | 2015-07-31 | 2017-02-09 | 이화여자대학교 산학협력단 | Novel cell penetrating peptide |
| CN109692327A (en) * | 2017-10-23 | 2019-04-30 | 华中科技大学 | A kind of application of the nano particle of the application and delivery melittin of melittin |
| CN108210883A (en) * | 2018-01-19 | 2018-06-29 | 东南大学 | A kind of nanometer reagent based on melittin and its preparation method and application |
| US20210244823A1 (en) * | 2018-05-04 | 2021-08-12 | Twinpigbiolab Inc. | Targeting m2-like tumor-associated macrophages by using melittin-based proapoptotic peptide |
| CN111909241A (en) * | 2020-07-09 | 2020-11-10 | 西安交通大学医学院第一附属医院 | Polypeptide nano hybrid and preparation method and application thereof |
| CN113512092A (en) * | 2021-06-28 | 2021-10-19 | 陕西未来多肽生物科技有限公司 | Polypeptide nano hybrid and application thereof |
| CN113952315A (en) * | 2021-11-08 | 2022-01-21 | 苏州迪拉纳生物科技有限公司 | Anticancer medicine and its prepn and application |
Non-Patent Citations (1)
| Title |
|---|
| 王磊 等: "蜂毒素在功能化金纳米粒子表面的吸附及构象变化", 高等学校化学学报, vol. 30, no. 1, pages 135 - 139 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8685440B2 (en) | Nanoliposome using esterified lecithin and method for preparing the same, and composition for preventing or treating skin diseases comprising the same | |
| HU220373B (en) | Preparation for improving the blood supply containing magnetically hard particles | |
| CN109330992B (en) | Polydopamine modified nano-structure lipid carrier and application thereof in intradermal drug delivery | |
| JP2004131502A (en) | Submicron-liposome containing triterpenoid at high concentration and method for preparing the same | |
| KR20180098695A (en) | Methods and compositions of bile acids and salts for reduction of fat | |
| US20210277062A9 (en) | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | |
| CN113301910A (en) | Skin rejuvenation and healing mixtures of peptide components and uses thereof | |
| WO2017009487A1 (en) | Topical compositions | |
| KR20180135444A (en) | Composition of Bioactive Fructate Fraction and its Use | |
| WO2017009485A1 (en) | Topical compositions | |
| CN114569628A (en) | Use of DNA tetrahedral framework nano-nucleic acid in cosmetology | |
| WO2017009486A1 (en) | Topical compositions | |
| WO2019029154A1 (en) | Transdermal composition and use thereof in preparation of transdermal formulation | |
| KR101775266B1 (en) | Novel tranexamic acid-loaded liquid crystalline nanoparticles and process for preparing the same | |
| CN114437193A (en) | Gold-melittin nano hybrid and application thereof | |
| AU2016321503B2 (en) | Highly stable non-vesicular nanoparticles and application thereof in treating microbial infection | |
| EP3329905A1 (en) | Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin | |
| WO2018014936A1 (en) | Topical compositions | |
| WO2004045619A1 (en) | Freeze-dried lecithin nanometer powder injection of ursolic acid and it's preparation method | |
| CN113134075A (en) | Antibacterial peptide emulsifiable paste and preparation method thereof | |
| TW201014614A (en) | Composition for preventing or treating chemotherapeutic agent-induced alopecia | |
| EP4371551A1 (en) | Molecular assembly of bile acid or bile salt and pharmaceutical composition comprising same for removing local fat | |
| CN113546046B (en) | Lactoferrin-modified patchouli alcohol liposome and preparation method and application thereof | |
| CN114621323B (en) | Polypeptide compound with skin repairing effect and preparation method and application thereof | |
| WO2023238416A1 (en) | Hair-growing or hair-fostering agent based on keratin fine particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |